As part of the fiscal cliff negotiations, the White House has trotted out a deeply misguided healthcare idea. The President has his allies want to loosen “intellectual property” protection for an advanced class of pharmaceuticals called “biologics.”

This is a mistake. Including this plan in any federal budget deal would inevitably undermine drug innovation, compromise care for millions of American patients, and — ironically — drive up long-term healthcare costs.

Recommended Stories

The Republican Party’s best closing ad is already on tape

The executive branch needs an executive

France prepares for another round of weekend protests